Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
No.2 Wei Yan Granule (also known as Wei Yan No. 2 Granule or Wei Yan No. 2 Formula) is an investigational traditional Chinese medicine (TCM) herbal formulation developed by Guangzhou University of Chinese Medicine. It is specifically formulated to treat the liver-stomach disharmony (肝胃不和) pattern of chronic superficial gastritis (also known as chronic non-atrophic gastritis). The formulation consists of multiple herbal ingredients, including Bupleurum (柴胡), Fructus Aurantii Immaturus (枳实), Radix Paeoniae Alba (白芍), and other traditional herbs, which work synergistically to soothe the liver, regulate qi, harmonize the stomach, and relieve pain. No.2 Wei Yan Granule has been evaluated in clinical trials in China, including a prospective, multicenter, randomized, double-blind controlled trial (ChiCTR-TRC-10000845) assessing its efficacy and safety compared to conventional active treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on No.2 Wei Yan Granule.